Crestor's global decline trickling down to Shionogi
This article was originally published in Scrip
Executive Summary
Shionogi is expecting royalty income from global licensee AstraZeneca for Crestor (rosuvastatin) to dip by around 2% to JPY62 billion ($620 million) this year, due to weakening worldwide sales of the high cholesterol drug.